Understanding the impact of disease causing mutations in FIX
Understanding the impact of disease causing mutations in FIX
批准号:
8752096
负责人:
Anton A. Komar
金额:
$43.65万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2018-07-31
关键词:
Activated Partial Thromboplastin Time measurementAffectAmino AcidsAnimal ModelBiological AssayBlood Coagulation DisordersBlood coagulationBrain hemorrhageCalnexinCell Culture SystemCell-Free SystemCellsCenters for Disease Control and Prevention (U.S.)ChemicalsCoagulantsCodon NucleotidesComputer SimulationDataDatabasesDiseaseF9 geneFactor IXFactor VIIaFactor XIaFoundationsGenotypeHematological DiseaseHemophilia AHemophilia BHemorrhageIn VitroKnowledgeLeadLocationMeasuresMessenger RNAModelingMolecularMolecular ChaperonesMonitorMutationMutation AnalysisNatureOpen Reading FramesPatientsPhenotypePost-Translational Protein ProcessingProcessPropertyProtein BiosynthesisProtein ConformationRNARNA SplicingRecombinant ProteinsReportingRiskSerine ProteaseSiteStructureSystemTestingTherapeuticThromboplastinTimeTranslationsTraumaVariantchemical propertydesigndisease-causing mutationdisorder preventiongene functionimprovedmRNA ExpressionmRNA Stabilitymutantprotein degradationprotein foldingpublic health relevance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hemophilia B is a blood clotting disorder caused by mutations in the F9 gene, encoding the blood coagulation
factor IX (FIX). Over 130 different non-synonymous mutations in F9 (which change encoded amino acids) and
at least 10 synonymous mutations (which do not change the encoded amino acids) cause the disease.
However, the effects of only a few have been analyzed to determine the exact mechanism(s) by which these
mutations contribute to FIX deficiency. Such knowledge is extremely important as these studies in particular
might help to improve the design of recombinant protein therapeutics. This proposal is focused on
understanding the exact effects produced by 3 non-synonymous (Val30Ile, Leu383Ile and Ala436Val) and 3
synonymous mutations (Val107Val, Arg162Arg and Gln237Gln) on the expressions, structure/activity of FIX.
We will conduct a comprehensive analysis of these mutations using in vitro (cell-free) and ex vivo (cell culture)
systems to assess their exact impact on FIX function. This project will add to our understanding of the
relationship between genotype and phenotype.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/srep31393
发表时间:
2016-08-11
期刊:
Scientific reports
影响因子:
4.6
作者:
[Singh J, Sikand K, Conrad H, Will CL, Komar AA, Shukla GC]
通讯作者:
Shukla GC
DOI:
10.1016/j.ymeth.2017.11.007
发表时间:
2018-03-15
期刊:
Methods (San Diego, Calif.)
影响因子:
--
作者:
[Komar AA]
通讯作者:
Komar AA
DOI:
10.1136/jmedgenet-2016-104072
发表时间:
2017-05
期刊:
Journal of medical genetics
影响因子:
4
作者:
[Simhadri VL, Hamasaki-Katagiri N, Lin BC, Hunt R, Jha S, Tseng SC, Wu A, Bentley AA, Zichel R, Lu Q, Zhu L, Freedberg DI, Monroe DM, Sauna ZE, Peters R, Komar AA, Kimchi-Sarfaty C]
通讯作者:
Kimchi-Sarfaty C
DOI:
10.1016/j.gene.2019.04.087
发表时间:
2019-07
期刊:
Gene
影响因子:
3.5
作者:
[Nishant Singh;Supriya Jindal;Arnab Ghosh;A. Komar]
通讯作者:
Nishant Singh;Supriya Jindal;Arnab Ghosh;A. Komar
DOI:
10.12688/f1000research.22400.2
发表时间:
2020
期刊:
F1000Research
影响因子:
--
作者:
[Alexaki A, Kames J, Hettiarachchi GK, Athey JC, Katneni UK, Hunt RC, Hamasaki-Katagiri N, Holcomb DD, DiCuccio M, Bar H, Komar AA, Kimchi-Sarfaty C]
通讯作者:
Kimchi-Sarfaty C
共 8 条
eIF2A in translational control
-
批准号:10348143
-
项目类别:
-
资助金额:$29.2万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
Safer and more effective FIX therapeutics: impact of codon optimization
-
批准号:10372111
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
Safer and more effective FIX therapeutics: impact of codon optimization
-
批准号:10600842
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
eIF2A in translational control
-
批准号:9883230
-
项目类别:
-
资助金额:$30.16万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
eIF2A in translational control
-
批准号:10539309
-
项目类别:
-
资助金额:$29.2万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
海外基金